Skip to content

LIDDS will participate in Redeye’s Fight Cancer Seminar on March 10

UPPSALA, SWEDEN – LIDDS AB (publ) – LIDDS CEO, Monica Wallter, will present the company at the Redeye Fight Cancer Seminar taking place in Stockholm on March 10, targeting both private and institutional investors and media. Monica will also take part in a panel debate together with other presenting companies at the seminar. The seminar gathers ten companies involved in developing different new treatment opportunities for fighting cancer.

Monica will be presenting LIDDS at 11.40 AM and take part in the panel discussion at 11.50 AM.

The seminar can be followed live at:

For more information, please contact:

Monica Wallter, CEO, +46 (0)737 07 09 22, e-mail:

LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology NanoZolid®. NanoZolid® is a clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. LIDDS (LIDDS) shares are listed on Nasdaq First North Growth Market. Redeye AB,, +46 (0)8 121 576 90, is a certified adviser to LIDDS. For more information, please visit